Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology

14.05.2024 | Review Article

Approach to the Atypical Wound

verfasst von: Sarah L. Becker, Shannon Kody, Nicole M. Fett, Alexander Hines, Afsaneh Alavi, Alex G. Ortega-Loayza

Erschienen in: American Journal of Clinical Dermatology

Einloggen, um Zugang zu erhalten

Abstract

The heterogeneity of atypical wounds can present diagnostic and therapeutic challenges; however, as the prevalence of atypical wounds grows worldwide, prompt and accurate management is increasingly an essential skill for dermatologists. Addressing the underlying cause of an atypical wound is critical for successful outcomes. An integrated approach with a focus on pain management and patient engagement is recommended to facilitate enduring wound closure. Advances in treatment, in addition to further research and clinical training, are necessary to address the expanding burden of atypical wounds.
Literatur
1.
2.
Shelling ML, Federman DG, Kirsner RS. Clinical approach to atypical wounds with a new model for understanding hypertensive ulcers. Arch Dermatol. 2010;146(9):1026–9.PubMedCrossRef
3.
Van Driessche FKR. Atypical wounds. In: Ayello EA, Barnoski S. Wound care essentials. Philadelphia: Lippincott Williams & Wilkins; 2016.
4.
5.
6.
de Araujo TKR. Atypical wounds. In: Ayello EA, Barnoski S. Wound care essentials. Philadelphia: Lippincott Williams & Wilkins; 2004.
7.
Mahmoudi M, Gould L. Opportunities and challenges of the management of chronic wounds: a multidisciplinary viewpoint. Chronic Wound Care Manag Res. 2020;7:27–36.CrossRef
8.
9.
10.
11.
Afsaneh Alavi HIM. Local wound care for dermatologists. 1st ed. Updates in clinical dermatology. Cham: Springer; 2020.CrossRef
12.
Solowiej K, Mason V, Upton D. Review of the relationship between stress and wound healing: part 1. J Wound Care. 2009;18(9):357–66.PubMedCrossRef
13.
14.
Woo K, Jimenez C. Quality of life and chronic wound care. In: Ayello EA, Barnoski S. Wound care essentials. Philadelphia: Lippincott Williams & Wilkins; 2016.
15.
Hopman WM, Harrison MB, Coo H, et al. Associations between chronic disease, age and physical and mental health status. Chronic Dis Can. 2009;29(3):108–16.PubMedCrossRef
16.
Shanmugam VK, Schilling A, Germinario A, et al. Prevalence of immune disease in patients with wounds presenting to a tertiary wound healing centre. Int Wound J. 2012;9(4):403–11.PubMedCrossRef
17.
Powers JG, Higham C, Broussard K, et al. Wound healing and treating wounds: Chronic wound care and management. J Am Acad Dermatol. 2016;74(4):607–25; quiz 25–6.PubMedCrossRef
18.
Tang JC, Vivas A, Rey A, et al. Atypical ulcers: wound biopsy results from a university wound pathology service . Ostomy Wound Manage. 2012;58(6):20–2, 4, 6–9.PubMed
19.
Haynes D, Hammer P, Malachowski SJ, et al. Characterisation and diagnosis of ulcers in inpatient dermatology consultation services: A multi-centre study. Int Wound J. 2019;16(6):1440–4.PubMedPubMedCentralCrossRef
20.
21.
Virkkala J, Polet S, Jokelainen J, et al. Clinical characteristics and comorbidities of the most common atypical wounds in Northern Finland in 1996–2019: A retrospective registry study. Health Sci Rep. 2022;5(5):e864.PubMedPubMedCentralCrossRef
22.
Ruiz ES, Ingram A, Landriscina A, et al. Identifying an education gap in wound care training in united states dermatology. J Drugs Dermatol. 2015;14(7):716–20.PubMed
23.
Erickson KM, Reese AM, Ortega-Loayza AG. Gap of knowledge in diagnosis of pyoderma gangrenosum in clinical specialties education. Diagnosis (Berl). 2021;8(4):421–4.PubMedCrossRef
24.
Shakshouk H, Lehman JS, Wu B, et al. Limb amputation in patients with pyoderma gangrenosum: a multi-institutional case series. Arch Dermatol Res. 2023;315(5):1443–8.PubMed
25.
26.
Xu A, Balgobind A, Strunk A, et al. Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis. J Am Acad Dermatol. 2020;83(2):425–9.PubMedCrossRef
27.
Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–8.PubMedCrossRef
28.
Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(4):479–87.PubMedCrossRef
29.
Al Ghazal P, Körber A, Klode J, et al. Investigation of new co-factors in 49 patients with pyoderma gangrenosum. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2012;10(4):251–6.PubMedCrossRef
30.
31.
Zhao H, Larson C, Schepergerdes BJ, Diefendorf CM, Ortega-Loayza AG, Mostaghimi A. Hundreds of inconsistencies in the nomenclature of pyoderma gangrenosum: The need to harmonise terminology for phenotypes. Int Wound J. 2024;21(1):e14357. https://​doi.​org/​10.​1111/​iwj.​14357.
32.
André MFJ, et al. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore). 2007;86(3):145–61.PubMedCrossRef
33.
Haag C, Hansen T, Hajar T, et al. Comparison of three diagnostic frameworks for pyoderma gangrenosum. J Invest Dermatol. 2021;141(1):59–63.PubMedCrossRef
34.
Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol. 2003;30(2):97–107.PubMedCrossRef
35.
Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244–50.PubMedCrossRef
36.
Hammer P, Latour E, Bohnett MC, et al. The utility and challenges of histopathologic evaluation in the diagnosis of nonmalignant skin ulcers. Wound Repair Regen. 2020;28(2):219–23.PubMedCrossRef
37.
Min MS, Kus K, Wei N, et al. Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study. Br J Dermatol. 2022;186(6):1035–7.PubMedCrossRef
38.
Ji-Xu A, Liakos W, Merleev A, et al. Assessing the discriminatory ability of diagnostic criteria for ulcerative pyoderma gangrenosum and its mimickers. JAMA Dermatol. 2023;159(3):337–8.PubMedPubMedCentralCrossRef
39.
Hodson EL, Salem I, Birkner M, et al. Real-world use of a deep convolutional neural network to assist in the diagnosis of pyoderma gangrenosum. JAAD Case Rep. 2023;38:8–10.PubMedPubMedCentralCrossRef
40.
41.
Janowska A, Davini G, Romanelli M, et al. The Association between pH and fluorescence as noninvasive diagnostic tools in chronic wounds. Int J Low Extrem Wounds. 2023;22(3):454–8.PubMedCrossRef
42.
MacLeod BG, Klarich CS, Wessman LL, et al. Fluorescent imaging as a component of diagnosing pyoderma gangrenosum: a case report. Adv Skin Wound Care. 2022;35(6):1–6.PubMedCrossRef
43.
44.
Goldust M, Hagstrom EL, Rathod D, et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. Expert Rev Clin Pharmacol. 2020;13(2):157–61.PubMedCrossRef
45.
46.
Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol. 2018;70(2):171–84.PubMedCrossRef
47.
Shakshouk H, Gibson LE. Cutaneous manifestations of ANCA-associated vasculitis: a retrospective review of 211 cases with emphasis on clinicopathologic correlation and ANCA status. Int J Dermatol. 2023;62(2):231–8.PubMedCrossRef
48.
Frumholtz L, Laurent-Roussel S, Aumaître O, et al. Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. Autoimmun Rev. 2017;16(11):1138–46.PubMedCrossRef
49.
Marzano AV, Raimondo MG, Berti E, et al. Cutaneous manifestations of ANCA-associated small vessels vasculitis. Clin Rev Allergy Immunol. 2017;53(3):428–38.PubMedCrossRef
50.
Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, et al. Cutaneous manifestations of granulomatosis with polyangiitis: a case series study. Acta Derm Venereol. 2020;100(10):adv00150.PubMedCrossRef
51.
Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.PubMedCrossRef
52.
Daoud MS, Hutton KP, Gibson LE. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol. 1997;136(5):706–13.PubMedCrossRef
53.
54.
Shavit E, Marzano AV, Alavi A. Ulcerative versus non-ulcerative panniculitis: is it time for a novel clinical approach to panniculitis? Int J Dermatol. 2021;60(4):407–17.PubMedCrossRef
55.
Gibson LE, Specks U, Homburger H. Clinical utility of ANCA tests for the dermatologist. Int J Dermatol. 2003;42(11):859–69.PubMedCrossRef
56.
Guchelaar NAD, Waling MM, Adhin AA, et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmun Rev. 2021;20(1):102716.PubMedCrossRef
57.
Stanson AW, Friese JL, Johnson CM, et al. Polyarteritis nodosa: spectrum of angiographic findings. Radiographics. 2001;21(1):151–9.PubMedCrossRef
58.
Bruce AJ, Bennett DD, Lohse CM, et al. Lipodermatosclerosis: review of cases evaluated at Mayo Clinic. J Am Acad Dermatol. 2002;46(2):187–92.PubMedCrossRef
59.
Savushkina NM, Egorova ON, Glukhova SI, et al. Panniculitis in rheumatology: features of course and outcomes. Ter Arkh. 2018;90(5):55–60.PubMed
60.
Fleischmajer R, Nedwich A. Generalized morphea. I. Histology of the dermis and subcutaneous tissue. Arch Dermatol. 1972;106(4):509–14.PubMedCrossRef
61.
Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations: dermatological, systemic and laboratory findings in 191 patients. Dermatology. 1995;190(4):277–83.PubMedCrossRef
62.
Rangel LK, Villa-Ruiz C, Lo K, et al. Clinical characteristics of lupus erythematosus panniculitis/profundus: a retrospective review of 61 patients. JAMA Dermatol. 2020;156(11):1264–6.PubMedPubMedCentralCrossRef
63.
Morita T, Trés GFS, García MSC, et al. Panniculitides of particular interest to the rheumatologist. Adv Rheumatol. 2019;59(1):35.PubMedCrossRef
64.
Bosisio F, Boi S, Caputo V, et al. Lobular panniculitic infiltrates with overlapping histopathologic features of lupus panniculitis (lupus profundus) and subcutaneous T-cell lymphoma: a conceptual and practical dilemma. Am J Surg Pathol. 2015;39(2):206–11.PubMedCrossRef
65.
66.
Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838–45.PubMedCrossRef
67.
Calderon LM, Pope JE. Scleroderma epidemiology update. Curr Opin Rheumatol. 2021;33(2):122–7.PubMedCrossRef
68.
69.
Herrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat Rev Rheumatol. 2022;18(5):276–85.PubMedPubMedCentralCrossRef
70.
Pagani K, Lukac D, Bhukhan A, et al. Cutaneous manifestations of inflammatory bowel disease: a basic overview. Am J Clin Dermatol. 2022;23(4):481–97.PubMedCrossRef
71.
Palamaras I, El-Jabbour J, Pietropaolo N, et al. Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol. 2008;22(9):1033–43.PubMedCrossRef
72.
Albertini JG, Tyler W, Miller OF 3rd. Ulcerative sarcoidosis: case report and review of the literature. Arch Dermatol. 1997;133(2):215–9.PubMedCrossRef
73.
Yoo SS, Mimouni D, Nikolskaia OV, et al. Clinicopathologic features of ulcerative-atrophic sarcoidosis. Int J Dermatol. 2004;43(2):108–12.PubMedCrossRef
74.
Noiles K, Beleznay K, Crawford RI, et al. Sarcoidosis can present with necrotizing granulomas histologically: two cases of ulcerated sarcoidosis and review of the literature. J Cutan Med Surg. 2013;17(6):377–83.PubMedCrossRef
75.
Reid SD, Ladizinski B, Lee K, et al. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol. 2013;69(5):783–91.PubMedCrossRef
76.
77.
Muller SA, Winkelmann RK. Necrobiosis lipoidica diabeticorum: a clinical and pathological investigation of 171 cases. Arch Dermatol. 1966;93(3):272–81.PubMedCrossRef
78.
Hines A, Butterfield R, Boudreaux B, et al. Characteristics of ulcerated and non-ulcerated necrobiosis lipoidica. Int J Dermatol. 2023;62(6):790–6.PubMedCrossRef
79.
Jorizzo JL, Olansky AJ, Stanley RJ. Superficial ulcerating necrobiosis in rheumatoid arthritis: a variant of the necrobiosis lipoidica-rheumatoid nodule spectrum? Arch Dermatol. 1982;118(4):255–9.PubMedCrossRef
80.
Peyrí J, Moreno A, Marcoval J. Necrobiosis lipoidica. Semin Cutan Med Surg. 2007;26(2):87–9.PubMedCrossRef
81.
Erfurt-Berge C, Seitz AT, Rehse C, et al. Update on clinical and laboratory features in necrobiosis lipoidica: a retrospective multicentre study of 52 patients. Eur J Dermatol. 2012;22(6):770–5.PubMedCrossRef
82.
Stanway A, Rademaker M, Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol. 2004;45(2):119–22.PubMedCrossRef
83.
Fay CJ, Iriarte C, Moslehi D, et al. Ulcerating necrobiotic xanthogranuloma: A clinical sign to reconsider progression from MGUS to multiple myeloma. JAAD Case Rep. 2023;40:1–3.PubMedPubMedCentralCrossRef
84.
Ferringer T, Miller F 3rd. Cutaneous manifestations of diabetes mellitus. Dermatol Clin. 2002;20(3):483–92.PubMedCrossRef
85.
Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am. 2013;42(4):869–98.PubMedCrossRef
86.
Jfri A, Nassim D, O’Brien E, et al. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatology. 2021;157(8):924–31.PubMedCrossRef
87.
Von Der Werth J, Williams H. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14(5):389–92.PubMedCrossRef
88.
Ring HC, Emtestam L. The microbiology of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):29–35.PubMedCrossRef
89.
Langan EA, Recke A, Bokor-Billmann T, et al. The Role of the cutaneous microbiome in hidradenitis suppurativa—light at the end of the microbiological tunnel. International Journal of Molecular Sciences. 2020;21(4):1205.PubMedPubMedCentralCrossRef
90.
91.
van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149(4):1150–61.PubMedCrossRef
92.
Pink A, Anzengruber F, Navarini AA. Acne and hidradenitis suppurativa. Br J Dermatol. 2018;178(3):619–31.PubMedCrossRef
93.
Siroy A, Wasman J. Metastatic Crohn disease: a rare cutaneous entity. Arch Pathol Lab Med. 2012;136(3):329–32.PubMedCrossRef
94.
Attanoos RL, Appleton MA, Hughes LE, et al. Granulomatous hidradenitis suppurativa and cutaneous Crohn's disease. Histopathology. 1993;23(2):111–5.PubMedCrossRef
95.
Katz RD, Goldberg NH. Marjolin ulcer arising within hidradenitis: a case report and literature review. Ann Plast Surg. 2009;62(2):173–4.PubMedCrossRef
96.
Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146(11):1265–70.PubMedCrossRef
97.
Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, et al. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):33–50.PubMedCrossRef
98.
Jachiet M, de Masson A, Peffault de Latour R, et al. Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity. British Journal of Dermatology. 2014;171(1):63–8.PubMedCrossRef
99.
Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109(7):2751–8.PubMedCrossRef
100.
Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.PubMedCrossRef
101.
Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-international society for cardiovascular infectious diseases criteria for infective endocarditis: updating the modified duke criteria. Clin Infect Dis. 2023;77(4):518–26.PubMedPubMedCentralCrossRef
102.
103.
Gogos C, Moschovidis V, Adamopoulos C, et al. A case series of skin manifestations of infective endocarditis in contemporary era: just another book finding or a useful clinical sign? Eur Heart J Case Rep. 2021;5(9):ytab345.PubMedPubMedCentralCrossRef
104.
Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022;41(10):2949–60.PubMedPubMedCentralCrossRef
105.
106.
Byramji A, Gilbert JD, Byard RW. Sudden death as a complication of bacterial endocarditis. Am J Forensic Med Pathol. 2011;32(2):140–2.PubMedCrossRef
107.
Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987;38(10):769–84.PubMedCrossRef
108.
Siow W, Chana J, Pawson R, et al. Type 1 cryoglobulinaemia leading to gangrene of the toes and ischaemic ulceration. Br J Haematol. 2018;181(6):724.PubMedCrossRef
109.
Trautmann A, Seitz CS. The complex clinical picture of side effects to anticoagulation. Med Clin N Am. 2010;94(4):821–34 (xii–iii).PubMedCrossRef
110.
Steuer AB, Cohen JM. The color of skin: purple diseases of the skin, nails, and mucosa. Clin Dermatol. 2019;37(5):528–47.PubMedCrossRef
111.
Rick J, Strowd L, Pasieka HB, et al. Calciphylaxis: Part I. Diagnosis and pathology. J Am Acad Dermatol. 2022;86(5):973–82.PubMedCrossRef
112.
McCarthy JT, et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc. 2016;91(10):1384–94.PubMedCrossRef
113.
Hayashi M. Calciphylaxis: diagnosis and clinical features. Clin Exp Nephrol. 2013;17(4):498–503.PubMedCrossRef
114.
Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378(18):1704–14.PubMedCrossRef
115.
Dobry AS, Nguyen ED, Shah R, et al. The role of skin biopsy in diagnosis and management of calciphylaxis: A retrospective analysis. Journal of the American Academy of Dermatology. 2021;85(3):765–7.PubMedCrossRef
116.
Vuerstaek J, Reeder S, Henquet C, et al. Arteriolosclerotic ulcer of Martorell. Journal of the European Academy of Dermatology and Venereology. 2010;24(8):867–74.PubMedCrossRef
117.
Hafner J, Nobbe S, Partsch H, et al. Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. Arch Dermatol. 2010;146(9):961–8.PubMedCrossRef
118.
Mansour M, Alavi A. Martorell ulcer: chronic wound management and rehabilitation. Chronic Wound Care Manag Res. 2019;6(null):83–8.CrossRef
119.
Alavi A, Mayer D, Hafner J, et al. Martorell hypertensive ischemic leg ulcer: an underdiagnosed Entity©. Adv Skin Wound Care. 2012;25(12):563–72; quiz 73–4.PubMedCrossRef
120.
Kolios AGA, Hafner J, Luder C, et al. Comparison of pyoderma gangrenosum and Martorell hypertensive ischaemic leg ulcer in a Swiss cohort. Br J Dermatol. 2018;178(2):e125–e6.PubMedCrossRef
121.
Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol. 1989;120(3):419–29.PubMedCrossRef
122.
Cañas CA, Durán CE, Bravo JC, et al. Leg ulcers in the antiphospholipid syndrome may be considered as a form of pyoderma gangrenosum and they respond favorably to treatment with immunosuppression and anticoagulation. Rheumatol Int. 2010;30(9):1253–7.PubMedCrossRef
123.
Giannakopoulos B, Passam F, Ioannou Y, et al. How we diagnose the antiphospholipid syndrome. Blood. 2009;113(5):985–94.PubMedCrossRef
124.
Alavi A, Hafner J, Dutz JP, et al. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol. 2013;69(6):1033–42.e1.PubMedCrossRef
125.
Di Giacomo TB, Hussein TP, Souza DG, et al. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs-a prospective study. J Eur Acad Dermatol Venereol. 2010;24(11):1340–6.PubMedCrossRef
126.
Seguí M, Llamas-Velasco M. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy. Front Med (Lausanne). 2022;9: 993515.PubMedPubMedCentralCrossRef
127.
128.
Trent JT, Kirsner RS. Leg ulcers in sickle cell disease. Adv Skin Wound Care. 2004;17(8):410–6.PubMedCrossRef
129.
Eckman JR. Leg ulcers in sickle cell disease. Hematol Oncol Clin N Am. 1996;10(6):1333–44.CrossRef
130.
Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood. 1989;74(4):1403–8.PubMedCrossRef
131.
Alavi A, Kirsner RS. Hemoglobinopathies and leg ulcers. Int J Low Extrem Wounds. 2015;14(3):213–6.PubMedCrossRef
132.
Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993;29(2 Pt 1):228–36.PubMedCrossRef
133.
Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of internal carcinoma. A retrospective study of 7316 cancer patients. J Am Acad Dermatol. 1990;22(1):19–26.PubMedCrossRef
134.
Hu SC, Chen GS, Wu CS, et al. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. J Am Acad Dermatol. 2009;60(3):379–87.PubMedCrossRef
135.
Schwartz RA. Cutaneous metastatic disease. J Am Acad Dermatol. 1995;33(2 Pt 1):161–82 (quiz 183–6).PubMedCrossRef
136.
Hu SC, Chen GS, Lu YW, et al. Cutaneous metastases from different internal malignancies: a clinical and prognostic appraisal. J Eur Acad Dermatol Venereol. 2008;22(6):735–40.PubMedCrossRef
137.
Corbett BE, BN, Markova A. comprehensive wound care for malignant wounds. In: M.H. Alavi A, editors. Local wound care for dermatologists: updates in clinical dermatology. Springer; 2020.
138.
139.
Kanth AM, Heiman AJ, Nair L, et al. Current trends in management of marjolin's ulcer: a systematic review. J Burn Care Res. 2021;42(2):144–51.PubMedCrossRef
140.
Thomson J, Hogan S, Leonardi-Bee J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020;11(11):Cd003412.PubMed
141.
Meaume S, Fromantin I, Teot L. Neoplastic wounds and degenerescence. J Tissue Viability. 2013;22(4):122–30.PubMedCrossRef
142.
Gjødsbøl K, Christensen JJ, Karlsmark T, et al. Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J. 2006;3(3):225–31.PubMedPubMedCentralCrossRef
143.
Vaiman M, et al. Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis. 2015;34(4):633–9.PubMedCrossRef
144.
145.
Oranges T, Veraldi S, Granieri G, et al. Parasites causing cutaneous wounds: Theory and practice from a dermatological point of view. Acta Tropica. 2022;228:106332.PubMedCrossRef
146.
Shields BE, Rosenbach M, Brown-Joel Z, et al. Angioinvasive fungal infections impacting the skin: Background, epidemiology, and clinical presentation. J Am Acad Dermatol. 2019;80(4):869–80.e5.PubMedCrossRef
147.
148.
149.
Chatterjee D, Saikia UN, Ramesh V. Diagnostic dilemma of cutaneous tuberculosis: opening of the Pandora’s box. Am J Dermatopathol. 2021;43(12):871–80.PubMedCrossRef
150.
151.
Fevereiro J, Sajjadi N, Fraga AG, et al. Individual and clinical variables associated with the risk of Buruli ulcer acquisition: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2020;14(4):e0008161.PubMedPubMedCentralCrossRef
152.
Gardner SE, Hillis SL, Heilmann K, et al. The neuropathic diabetic foot ulcer microbiome is associated with clinical factors. Diabetes. 2013;62(3):923–30.PubMedPubMedCentralCrossRef
153.
Loesche M, Gardner SE, Kalan L, et al. Temporal stability in chronic wound microbiota is associated with poor healing. J Invest Dermatol. 2017;137(1):237–44.PubMedCrossRef
154.
155.
Ortega-Loayza AG, McCall CO. Images in clinical medicine: cutaneous blastomycosis. N Engl J Med. 2013;368(10): e13.PubMedCrossRef
156.
Gattringer C, Scheurecker C, Höpfl R, et al. Association between venous leg ulcers and sex chromosome anomalies in men. Acta Derm Venereol. 2010;90(6):612–5.PubMedCrossRef
157.
Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152(11):1231–8.PubMedCrossRef
158.
Tang JY, Marinkovich MP, Lucas E, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1):175.PubMedPubMedCentralCrossRef
159.
Sangha N, MacLellan AN, Pope E. Psychosocial impact of epidermolysis bullosa on patients: a qualitative study. Pediatr Dermatol. 2021;38(4):819–24.PubMedCrossRef
160.
Mauritz PJ, Bolling M, Duipmans JC, et al. Patients' and parents' experiences during wound care of epidermolysis bullosa from a dyadic perspective: a survey study. Orphanet J Rare Dis. 2022;17(1):313.PubMedPubMedCentralCrossRef
161.
Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.PubMedPubMedCentralCrossRef
162.
South AP, Laimer M, Gueye M, et al. Type VII collagen deficiency in the oncogenesis of cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa. J Invest Dermatol. 2023;143(11):2108–19.PubMedCrossRef
163.
D'Epiro S, Salvi M, Luzi A, et al. Drug cutaneous side effect: focus on skin ulceration. Clin Ter. 2014;165(4):e323–9.PubMed
164.
Wei KC, Yang KC, Mar GY, et al. STROBE-radiation ulcer: an overlooked complication of fluoroscopic intervention: a cross-sectional study. Medicine (Baltimore). 2015;94(48):e2178.PubMedCrossRef
165.
Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006;54(1):28–46.PubMedCrossRef
166.
Hegedus F, Mathew LM, Schwartz RA. Radiation dermatitis: an overview. Int J Dermatol. 2017;56(9):909–14.PubMedCrossRef
167.
Duron D, Blaise S, Cracowski J-L, et al. Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database. Journal of the American Academy of Dermatology. 2021;85(1):229–32.PubMedCrossRef
168.
Zhang M, Hassan KM, Musiek A, et al. Ponatinib-induced neutrophilic panniculitis. J Cutan Pathol. 2014;41(7):597–601.PubMedCrossRef
169.
Stewart J, Bayers S, Vandergriff T. Self-limiting ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol. 2018;40(2):e28–9.PubMedCrossRef
170.
Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2017;177(1):72–83.PubMedCrossRef
171.
Gormley R, Wanat K, Elenitsas R, et al. Ipilimumab-associated Sweet syndrome in a melanoma patient. J Am Acad Dermatol. 2014;71(5):e211–3.PubMedCrossRef
172.
Adler NR, Murray WK, Brady B, et al. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma. Clin Exp Dermatol. 2018;43(4):497–9.PubMedCrossRef
173.
Kyllo RL, Parker MK, Rosman I, et al. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol. 2014;70(4):e85–e6.PubMedCrossRef
174.
Pintova S, Sidhu H, Friedlander PA, et al. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498–501.PubMedCrossRef
175.
176.
Wei J, Wachuku C, Berk-Krauss J, et al. Severe cutaneous ulcerations secondary to xylazine (tranq): A case series. JAAD Case Reports. 2023;36:89–91.PubMedPubMedCentralCrossRef
177.
Harth W, Taube K-M, Gieler U. Facticious disorders in dermatology. JDDG. 2010;8(5):361–73.PubMed
178.
Uçmak D, Harman M, Akkurt ZM. Dermatitis artefacta: a retrospective analysis. Cutan Ocul Toxicol. 2014;33(1):22–7.PubMedCrossRef
179.
Van Moffaert M. Training future dermatologists in psychodermatology. Gen Hosp Psychiatry. 1986;8(2):115–8.PubMedCrossRef
180.
Khan AU, Khachemoune A. Trigeminal trophic syndrome: an updated review. Int J Dermatol. 2019;58(5):530–7.PubMedCrossRef
181.
Rashid RM, Khachemoune A. Trigeminal trophic syndrome. J Eur Acad Dermatol Venereol. 2007;21(6):725–31.PubMedCrossRef
182.
Sawada T, Asai J, Nomiyama T, et al. Trigeminal trophic syndrome: report of a case and review of the published work. J Dermatol. 2014;41(6):525–8.PubMedCrossRef
183.
Alivernini S, De Santis M, Tolusso B, et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol. 2009;60(3):426–35.PubMedCrossRef
184.
Ayello EA. What does the wound say? Why determining etiology is essential for appropriate wound care. Adv Skin Wound Care. 2005;18(2):98–109 (quiz 110–1).PubMedCrossRef
185.
Dissemond J, Romanelli M. Inflammatory skin diseases and wounds. Br J Dermatol. 2022;187(2):167–77.PubMedCrossRef
186.
Keast DH, Bowering CK, Evans AW, et al. MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessment. Wound Repair Regen. 2004;12(3 Suppl):S1–17.PubMed
187.
Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen. 2000;8(5):347–52.PubMedCrossRef
188.
Sibbald RG, Williamson D, Orsted HL, et al. Preparing the wound bed-debridement, bacterial balance, and moisture balance. Ostomy Wound Manage. 2000;46(11):14–22, 4–8, 30–5; quiz 6–7.
189.
Atkin L, Bućko Z, Montero EC, et al. Implementing TIMERS: the race against hard-to-heal wounds. J Wound Care. 2019;28(Sup3a):S1–50.CrossRef
190.
Woo KY. Management of non-healable or maintenance wounds with topical povidone iodine. Int Wound J. 2014;11(6):622–6.PubMedCrossRef
191.
Hines A, Kody S, Shakshouk H, et al. Inflammatory and vaso-occlusive ulcers: Part II - Management. J Am Acad Dermatol. 2024.
192.
Moelleken M, Krimphove SH, Krefting F, et al. How effective is simple mechanical wound debridement in reducing bacterial colonisation? Results of a prospective clinical study. Int Wound J. 2024;21(4):e14824.PubMedPubMedCentralCrossRef
193.
Dissemond J, Eder S, Läuchli S, et al. [Compression therapy for inflammatory dermatoses of the legs]. Dtsch Med Wochenschr. 2024;149(3):106–12.PubMed
194.
Chen AH, Frangos SG, Kilaru S, et al. Intermittent pneumatic compression devices - physiological mechanisms of action. Eur J Vasc Endovasc Surg. 2001;21(5):383–92.PubMedCrossRef
195.
196.
Stevenson EM, Coda A, Bourke MDJ. Investigating low rates of compliance to graduated compression therapy for chronic venous insufficiency: a systematic review. Int Wound J. 2024;21(4): e14833.PubMedPubMedCentralCrossRef
197.
Snyder DSN, Margolis D, et al. Skin substitutes for treating chronic wounds. Rockville: Agency for Healthcare Research and Quality; 2020.
198.
Sierra-Sánchez Á, Kim KH, Blasco-Morente G, et al. Cellular human tissue-engineered skin substitutes investigated for deep and difficult to heal injuries. NPJ Regen Med. 2021;6(1):35.PubMedPubMedCentralCrossRef
199.
Kranke P, Bennett MH, Martyn-St James M, et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev. 2015;2015(6):Cd004123.PubMedPubMedCentral
200.
Bennett MH, Feldmeier J, Hampson NB, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2016;4(4):Cd005005.PubMed
201.
Orgill DP, Manders EK, Sumpio BE, et al. The mechanisms of action of vacuum assisted closure: more to learn. Surgery. 2009;146(1):40–51.PubMedCrossRef
202.
Eisendle K, Thuile T, Deluca J, et al. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and skin grafting, including xenografts: personal experience and comprehensive review on 161 cases. Adv Wound Care (New Rochelle). 2020;9(7):405–25.PubMedPubMedCentralCrossRef
203.
Erickson KM, Kody S, Ortega-Loayza AG. Pain as a patient-reported outcome measure in pyoderma gangrenosum. JAMA Dermatol. 2023;159(11):1274–5.PubMedCrossRef
204.
Beiteke U, Bigge S, Reichenberger C, et al. Pain and pain management in dermatology. J Dtsch Dermatol Ges. 2015;13(10):967–87.PubMed
205.
Janowska A, Papa G, Romanelli M, et al. 5% Lidocaine hydrochloride cream for wound pain relief: a multicentre observational study. J Invest Surg. 2022;35(1):49–52.PubMedCrossRef
206.
de Leon J, Bohn GA, DiDomenico L, et al. Wound care centers: critical thinking and treatment strategies for wounds. Wounds. 2016;28(10):S1–23.PubMed
207.
Fayne RA, Borda LJ, Egger AN, et al. The potential impact of social genomics on wound healing. Adv Wound Care (New Rochelle). 2020;9(6):325–31.PubMedPubMedCentralCrossRef
208.
Pierpont YN, Dinh TP, Salas RE, et al. Obesity and surgical wound healing: a current review. ISRN Obes. 2014;2014:638936.PubMedPubMedCentral
209.
Mahmoudi MGL. Opportunities and challenges of the management of chronic wounds: a multidisciplinary viewpoint. Chronic Wound Care Manag Res. 2020;7:27–36.CrossRef
210.
211.
Ahuja S, Briggs SM, Collier SM. Teledermatology in rural, underserved, and isolated environments: a review. Curr Dermatol Rep. 2022;11(4):328–35.PubMedPubMedCentralCrossRef
212.
Stojadinovic O, Brem H, Vouthounis C, et al. Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing. Am J Pathol. 2005;167(1):59–69.PubMedPubMedCentralCrossRef
213.
214.
De Pessemier B, Grine L, Debaere M, et al. Gut–Skin Axis: Current knowledge of the interrelationship between microbial dysbiosis and skin conditions. Microorganisms. 2021;9(2):353.PubMedPubMedCentralCrossRef
215.
Rick J, Gould LJ, Marzano AV, et al. The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum. Arch Dermatol Res. 2023;315(4):983–8.PubMedCrossRef
216.
Kohn AH, Alavi A, Armstrong AW, et al. International dermatology outcome measures (IDEOM): report from the 2020 annual meeting. Dermatology. 2022;238(3):430–7.PubMedCrossRef
217.
Orfaly VE, Reese AM, Friedman M, et al. Pyoderma gangrenosum study pilot registry: The first step to a better understanding. Wound Repair Regen. 2022;30(3):334–7.PubMedCrossRef
218.
Haddadin OM, Jacobson ME, Chen DM, et al. Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative. Arch Dermatol Res. 2023;315(10):2913–9.PubMedCrossRef
219.
Patel NP, Granick MS. Wound education: American medical students are inadequately trained in wound care. Ann Plast Surg. 2007;59(1):53–5 (discussion 55).PubMedCrossRef
220.
Patel NP, Granick MS, Kanakaris NK, et al. Comparison of wound education in medical schools in the United States, United kingdom, and Germany. Eplasty. 2008;8:e8.PubMedPubMedCentral
221.
Khoobyari S, Miller TI, Shinohara MM. Utility of skin biopsy and culture in the diagnosis and classification of chronic ulcers: a single-institution, retrospective study. Am J Dermatopathol. 2019;41(5):343–6.PubMedCrossRef
222.
Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum. Nature Reviews Disease Primers. 2020;6(1):81.PubMedCrossRef
223.
Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132(9):2166–70.PubMedCrossRef
224.
Hashemi DA, Brown-Joel ZO, Tkachenko E, et al. Clinical features and comorbidities of patients with necrobiosis lipoidica with or without diabetes. JAMA Dermatology. 2019;155(4):455–9.PubMedPubMedCentralCrossRef
225.
Kirsten N, Petersen J, Hagenström K, et al. Epidemiology of hidradenitis suppurativa in Germany – an observational cohort study based on a multisource approach. Journal of the European Academy of Dermatology and Venereology. 2020;34(1):174–9.PubMedCrossRef
226.
Peoples C, Medsger TA, Jr., Lucas M, et al. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord. 2016;1(2):177–240.PubMed
227.
Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–28.PubMedCrossRef
228.
Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Archives of Dermatology. 2009;145(5):545–50.PubMedPubMedCentralCrossRef
229.
Bergamasco A, Hartmann N, Wallace L, et al. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019;11:257–73.PubMedPubMedCentralCrossRef
230.
Gardette E, Moguelet P, Bouaziz JD, et al. Livedoid vasculopathy: a french observational study including therapeutic options. Acta Derm Venereol. 2018;98(9):842–7.PubMedCrossRef
231.
Jeong HS, Dominguez AR. Calciphylaxis: controversies in pathogenesis, diagnosis and treatment. Am J Med Sci. 2016;351(2):217–27.PubMedCrossRef
232.
233.
Yamamoto T, Yamasaki K, Yamanaka K, et al. Clinical guidance of pyoderma gangrenosum 2022. J Dermatol. 2023;50(9):e253–e75.PubMedCrossRef
234.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30–47.PubMedCrossRef
235.
Chung SA, Langford CA, Maz M, et al. 2021 American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366–83.PubMedCrossRef
236.
Klejtman T, Lazareth I, Yannoutsos A, et al. Specific management of lipodermatosclerosis (sclerotic hypodermitis) in acute and chronic phase. JMV-Journal de Médecine Vasculaire. 2022;47(4):186–90.PubMed
237.
238.
Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91–101.PubMedPubMedCentralCrossRef
239.
Teske N, Fett N. Recent advances in treatment of systemic sclerosis and morphea. Am J Clin Dermatol. 2024;25(2):213–26.PubMedCrossRef
240.
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39.PubMedCrossRef
241.
Rick J, Rrapi R, Chand S, et al. Calciphylaxis: Treatment and outlook-CME part II. J Am Acad Dermatol. 2022;86(5):985–92.PubMedCrossRef
Metadaten
Titel
Approach to the Atypical Wound
verfasst von
Sarah L. Becker
Shannon Kody
Nicole M. Fett
Alexander Hines
Afsaneh Alavi
Alex G. Ortega-Loayza
Publikationsdatum
14.05.2024
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-024-00865-0

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise